{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:31:07Z","timestamp":1794317467906,"version":"4.9.0"},"reference-count":43,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2018,1,12]]},"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Two recombinant enzymes (agalsidase alfa 0.2\u2009mg\/kg\/every other week and agalsidase beta 1.0\u2009mg\/kg\/every other week) have been registered for the treatment of Fabry disease (FD), at equal high costs. An independent international initiative compared clinical and biochemical outcomes of the two enzymes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicentre retrospective cohort study, clinical event rate, left ventricular mass index (LVMI), estimated glomerular filtration rate (eGFR), antibody formation and globotriaosylsphingosine (lysoGb3) levels were compared between patients with FD treated with agalsidase alfa and beta at their registered dose after correction for phenotype and sex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>387 patients (192 women) were included, 248 patients received agalsidase alfa. Mean age at start of enzyme replacement therapy was 46 (\u00b115) years. Propensity score matched analysis revealed a similar event rate for both enzymes (HR 0.96, P=0.87). The decrease in plasma lysoGb3 was more robust following treatment with agalsidase beta, specifically in men with classical FD (\u03b2: \u221218\u2009nmol\/L, P&lt;0.001), persisting in the presence of antibodies. The risk to develop antibodies was higher for patients treated with agalsidase beta (OR 2.8, P=0.04). LVMI decreased in a higher proportion following the first year of agalsidase beta treatment (OR 2.27, P=0.03), while eGFR slopes were similar.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment with agalsidase beta at higher dose compared with agalsidase alfa does not result in a difference in clinical events, which occurred especially in those with more advanced disease. A greater biochemical response, also in the presence of antibodies, and better reduction in left ventricular mass was observed with agalsidase beta.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jmedgenet-2017-104863","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T12:20:26Z","timestamp":1518006026000},"page":"351-358","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":116,"title":["Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study"],"prefix":"10.1136","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3016-1572","authenticated-orcid":false,"given":"Maarten","family":"Arends","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Biegstraaten","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Nephrology and Cardiology, Comprehensive Heart Failure Center (CHFC) and Fabry Center for Interdisciplinary Therapy (FAZIT), University Hospital Wuerzburg, Wuerzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sirrs","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal Free London NHS Foundation Trust and University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry M","family":"Elliott","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St Bartholomew\u2019s Hospital, London, UK"},{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Oder","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Nephrology and Cardiology, Comprehensive Heart Failure Center (CHFC) and Fabry Center for Interdisciplinary Therapy (FAZIT), University Hospital Wuerzburg, Wuerzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver T","family":"Watkinson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St Bartholomew\u2019s Hospital, London, UK"},{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G","family":"Bichet","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Montreal, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneal","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Iwanochko","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric M","family":"Vaz","sequence":"additional","affiliation":[{"name":"Laboratory Genetic Metabolic Diseases, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 B P","family":"van Kuilenburg","sequence":"additional","affiliation":[{"name":"Laboratory Genetic Metabolic Diseases, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L","family":"West","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn A","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal Free London NHS Foundation Trust and University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla E M","family":"Hollak","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,2,7]]},"reference":[{"key":"2025101714285152000_55.5.351.1","unstructured":"Desnick RJ , Ioannou YA , Eng CM . et al \u0391-galactosidase a deficiency: fabry disease. In: Valle D , Beaudet AL , Vogelstein B , Kinzler KW , Antonarakis SE , Ballabio A , Gibson KMG , . eds. OMMBID - The Online Metabolic and Molecular Bases of Inherited Diseases. New York: McGraw-Hill, 2013."},{"key":"2025101714285152000_55.5.351.2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0712309105"},{"key":"2025101714285152000_55.5.351.3","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2014-102872"},{"key":"2025101714285152000_55.5.351.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-352971"},{"key":"2025101714285152000_55.5.351.5","first-page":"83","article-title":"Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up","volume":"17","author":"van der Tol","year":"2014","journal-title":"JIMD Rep"},{"key":"2025101714285152000_55.5.351.6","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.38.11.769"},{"key":"2025101714285152000_55.5.351.7","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016090964"},{"key":"2025101714285152000_55.5.351.8","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwg034"},{"key":"2025101714285152000_55.5.351.9","doi-asserted-by":"publisher","DOI":"10.1086\/345309"},{"key":"2025101714285152000_55.5.351.10","doi-asserted-by":"publisher","DOI":"10.1007\/s10038-005-0342-9"},{"key":"2025101714285152000_55.5.351.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.21.2743"},{"key":"2025101714285152000_55.5.351.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107053450102"},{"key":"2025101714285152000_55.5.351.13","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-47"},{"key":"2025101714285152000_55.5.351.14","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12077"},{"key":"2025101714285152000_55.5.351.15","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-2-200701160-00148"},{"key":"2025101714285152000_55.5.351.16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg","volume":"2","author":"Vedder","year":"2007","journal-title":"PLoS One"},{"key":"2025101714285152000_55.5.351.17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"1812","author":"van Breemen","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"2025101714285152000_55.5.351.18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry disease initiative","volume":"111","author":"Sirrs","year":"2014","journal-title":"Mol Genet Metab"},{"key":"2025101714285152000_55.5.351.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase a in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS One"},{"key":"2025101714285152000_55.5.351.20","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014121226"},{"key":"2025101714285152000_55.5.351.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2009.11.001"},{"key":"2025101714285152000_55.5.351.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.09.001"},{"key":"2025101714285152000_55.5.351.23","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008030287"},{"key":"2025101714285152000_55.5.351.24","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.73"},{"key":"2025101714285152000_55.5.351.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2005.10.005"},{"key":"2025101714285152000_55.5.351.26","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2012.192138"},{"key":"2025101714285152000_55.5.351.27","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jchromb.2011.11.020","article-title":"Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry","volume":"883-884","author":"Kr\u00fcger","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2025101714285152000_55.5.351.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00924.x"},{"key":"2025101714285152000_55.5.351.29","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"2025101714285152000_55.5.351.30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182379","article-title":"Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors","volume":"12","author":"Arends","year":"2017","journal-title":"PLoS One"},{"key":"2025101714285152000_55.5.351.31","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-69"},{"key":"2025101714285152000_55.5.351.32","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012030316"},{"key":"2025101714285152000_55.5.351.33","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-011-9400-y"},{"key":"2025101714285152000_55.5.351.34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-5072"},{"key":"2025101714285152000_55.5.351.35","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.12104"},{"key":"2025101714285152000_55.5.351.36","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.112.195685"},{"key":"2025101714285152000_55.5.351.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2008.03.003"},{"key":"2025101714285152000_55.5.351.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2008.10.004"},{"key":"2025101714285152000_55.5.351.39","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-116"},{"key":"2025101714285152000_55.5.351.40","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/gim.2014.28","article-title":"Clinical course of patients with Fabry disease who were switched from agalsidase-\u03b2 to agalsidase-\u03b1","volume":"16","author":"Tsuboi","year":"2014","journal-title":"Genet Med"},{"key":"2025101714285152000_55.5.351.41","first-page":"41","article-title":"Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease","volume":"9","author":"Pisani","year":"2013","journal-title":"JIMD Rep"},{"key":"2025101714285152000_55.5.351.42","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015030337"},{"key":"2025101714285152000_55.5.351.43","unstructured":"Zon MW . Treatment of patients with Fabry disease with agalsidase alfa and agalsidase beta: phenotypic diversity necessitates the development of individualized treatment guidelines. 2013 https:\/\/www.zonmw.nl\/nl\/onderzoek-resultaten\/doelmatigheidsonderzoek\/programmas\/project-detail\/goed-gebruik-geneesmiddelen\/treatment-of-patients-with-fabry-disease-with-agalsidase-alfa-and-agalsidase-beta-phenotypic-divers\/ (accessed 15 Jan 2017)."}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmedgenet-2017-104863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T21:28:58Z","timestamp":1760736538000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmedgenet-2017-104863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,7]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,4,27]]},"published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1136\/jmedgenet-2017-104863"],"URL":"https:\/\/doi.org\/10.1136\/jmedgenet-2017-104863","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/jmedgenet-2017-104863.supp1","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/jmedgenet-2017-104863.supp2","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/jmedgenet-2017-104863.supp3","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/jmedgenet-2017-104863.supp4","asserted-by":"subject"}]},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,7]]}}}